EGRX logo

Eagle Pharmaceuticals (EGRX)

Profile

Full Name

Eagle Pharmaceuticals, Inc.

Ticker Symbol

EGRX

Exchange

NASDAQ

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

United States

IPO

February 12, 2014

Indexes

Not included

Website

http://www.eagleus.com

Employees

134

Key Details

Price

$1.25(+4.17%)

Market cap

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$316.61M(+84.56% YoY)

Annual EPS

$2.73(+513.64% YoY)

PE ratio

1.37

Next earnings date

May 15, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Current Price

$1.25
EGRX price is $1.25

30-Day Relative Volume

1.08
EGRX 30-day relative volume is 1.08

Price Performance

Price Most recent change

+4.17%
EGRX price was up +4.17% on Apr 14, 2025

Price YTD change

+150%
EGRX price is up +150% since January 1st

Price 1-year change

-72.77%
EGRX price is down -72.77% year-on-year

Price 3-year change

-97.52%
EGRX price is down -97.52% over the past 3 years

Price Range

Price All-time high

$104.17
EGRX price is currently -98.80% below its historical high of $104.17

Price 3-year low

$0.00
EGRX price is currently >+9900.00% above its 3-year low

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Market cap

$16.23M
EGRX market capitalization is $16.23 million

Market cap 3-year change

-97.47%
EGRX market capitalization is down -97.47% over the past 3 years

Market cap All-time high

$1.57B
EGRX market capitalization is currently -98.96% below its historical high of $1.57 billion

Market cap sector rank

25.33%
EGRX market capitalization is higher than 25.33% of companies in Healthcare sector

Shares Outstanding

Shares Outstanding 1-Year Change

0%
EGRX {parameterFullLabel} has remained unchanged year-on-year

Shares Outstanding 3-Year Change

+2.28%
EGRX shares outstanding is up +2.28% over the past 3 years

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Beta

0.60
EGRX beta is 0.60

200-day SMA

$2.21
EGRX price is currently -43.34% below its 200-day simple moving average

50-day SMA

$1.22
EGRX price is currently +2.05% above its 50-day simple moving average

RSI

48.57
EGRX 14-day relative strength index is 48.57

Volume

1.08
EGRX 30-day relative volume is 1.08

ATR

$0.46
EGRX average true range is $0.46

10-day Historical Volatility

374.75%
EGRX 10-day historical volatility is 374.75%

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Revenue

$316.61M
EGRX annual revenue is $316.61 million

Revenue Analysts estimate

$258.29M
EGRX annual revenue is currently +22.58% higher than the consensus analysts' forecast

Revenue 1-year change

+84.56%
EGRX annual revenue is up +84.56% year-on-year

Revenue Sector rank

69.43%
EGRX annual revenue is higher than 69.43% of companies in Healthcare sector

EPS

EPS

$2.73
EGRX annual earnings per share is $2.73

EPS Analysts estimate

-
EGRX annual earnings per share consensus analysts' forecast is unknown

EPS 1-year change

+513.64%
EGRX annual earnings per share is up +513.64% year-on-year

EPS Sector rank

93.47%
EGRX annual earnings per share is higher than 93.47% of companies in Healthcare sector

Profit

Gross profit

$221.67M
EGRX annual gross profit is $221.67 million

Gross margin

70.01%
EGRX annual gross profit margin is 70.01%

Operating profit

$80.96M
EGRX annual operating income is $80.96 million

Operating margin

25.57%
EGRX annual operating profit margin is 25.57%

Net income

$35.64M
EGRX annual net profit is $35.64 million

Net margin

11.26%
EGRX annual net profit margin is 11.26%

Expenses

Total expenses

$235.65M
EGRX annual total expenses is $235.65 million

Operating expenses

$140.71M
EGRX annual total operating expenses is $140.71 million

Cost of goods sold

$94.94M
EGRX annual cost of goods sold is $94.94 million

Selling, general & administrative expenses

$106.63M
EGRX annual SGA is $106.63 million

Depreciation and amortization

$12.02M
EGRX annual depreciation & amortization is $12.02 million

Interest expense

$4.04M
EGRX annual interest expense is $4.04 million

Income tax

$25.79M
EGRX annual income tax is $25.79 million

EBIT & EBITDA

EBIT

$65.48M
EGRX annual earnings before interest & taxes is $65.48 million

EBITDA

$65.48M
EGRX annual EBITDA is $65.48 million

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Total assets

$406.16M
EGRX annual total assets is $406.16 million

Non current assets

$217.41M
EGRX annual long term assets is $217.41 million

Current assets

$188.75M
EGRX annual total current assets is $188.75 million

Cash and cash equivalents

$55.32M
EGRX annual cash & cash equivalents is $55.32 million

Accounts receivable

$72.44M
EGRX annual accounts receivable is $72.44 million

Inventory

$47.79M
EGRX annual inventory is $47.79 million

Liabilities

Total liabilities

$172.60M
EGRX annual total liabilities is $172.60 million

Long term liabilities

$61.51M
EGRX annual total long term liabilities is $61.51 million

Current liabilities

$111.09M
EGRX annual total current liabilities is $111.09 million

Accounts payable

$18.99M
EGRX annual accounts payable is $18.99 million

Debt

Total debt

$62.47M
EGRX annual total debt is $62.47 million

Total debt 1-year change

+132.08%
EGRX annual total debt is up +132.08% year-on-year

Long term debt

$56.22M
EGRX annual long term debt is $56.22 million

Short term debt

$6.25M
EGRX annual short term debt is $6.25 million

Equity & Capital

Shareholders equity

$233.56M
EGRX annual stockholders equity is $233.56 million

Book value

$233.56M
EGRX annual book value is $233.56 million

Retained earnings

$111.50M
EGRX annual retained earnings is $111.50 million

Working capital

$77.67M
EGRX annual working capital is $77.67 million

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Cash from operations

$50.70M
EGRX annual cash flow from operations is $50.70 million

Cash from operations 1-year change

+79.67%
EGRX annual cash flow from operations is up +79.67% year-on-year

Cash from investing

-$86.83M
EGRX annual cash flow from investing activities is -$86.83 million

Cash from investing 1-year change

-1531.22%
EGRX annual cash flow from investing activities is down -1531.22% year-on-year

Cash from financing

-$6.21M
EGRX annual cash flow from financing activities is -$6.21 million

Cash from financing 1-year change

+78.13%
EGRX annual cash flow from financing activities is up +78.13% year-on-year

CAPEX

CAPEX

$178.00K
EGRX annual capital expenditures is $178.00 thousand

CAPEX 1-year change

-44.89%
EGRX annual capital expenditures is down -44.89% year-on-year

Free Cash Flow

Free cash flow

$50.52M
EGRX annual free cash flow is $50.52 million

Free cash flow 1-year change

+81.11%
EGRX annual free cash flow is up +81.11% year-on-year

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

Gross margin

70.01%
EGRX annual gross profit margin is 70.01%

Operating margin

25.57%
EGRX annual operating profit margin is 25.57%

Net margin

11.26%
EGRX annual net profit margin is 11.26%

ROA & ROE

ROA

10.80%
EGRX annual return on assets is 10.80%

ROE

17.39%
EGRX annual return on equity is 17.39%

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PE ratio

1.37
EGRX price to earnings ratio is 1.37

PE ratio Sector rank

2.94%
EGRX price to earnings ratio is higher than 2.94% of companies in Healthcare sector

PB Ratio

PB ratio

0.06
EGRX price to book ratio is 0.06

PB ratio Sector rank

17.53%
EGRX price to book ratio is higher than 17.53% of companies in Healthcare sector

PS Ratio

PS ratio

0.06
EGRX price to sales ratio is 0.06

PS ratio Sector rank

4.23%
EGRX price to sales ratio is higher than 4.23% of companies in Healthcare sector

Enterprise value

Enterprise value

$72.49M
EGRX enterprise value is $72.49 million

Enterprise value Sector rank

45.79%
EGRX enterprise value is higher than 45.79% of companies in Healthcare sector

EV/EBITDA

EV/EBITDA

1.29
EGRX EV/EBITDA is 1.29

EV/EBITDA Sector rank

75.3%
EGRX EV/EBITDA is higher than 75.3% of companies in Healthcare sector

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Current ratio

1.70
EGRX annual current ratio is 1.70

Quick ratio

1.27
EGRX annual quick ratio is 1.27

Leverage

Debt to equity

0.27
EGRX annual debt to equity ratio is 0.27

Interest coverage ratio

16.19
EGRX annual interest coverage ratio is 16.19

Risk & Stability

Piotroski F-Score

5
EGRX piotroski f-score is 5

Altman Z-Score

1.98
EGRX altman z-score is 1.98

Analyst ratings

Recent major analysts updates

Aug 9, 23 Piper Sandler
Underweight
Mar 2, 20 Cantor Fitzgerald
Neutral
Mar 22, 19 Mizuho
Neutral
Oct 31, 18 PiperJaffray
Neutral
Oct 31, 18 Piper Sandler
Neutral
Sep 21, 18 Cantor Fitzgerald
Overweight
Jun 12, 18 Cantor Fitzgerald
Overweight
Jun 11, 18 Mizuho
Neutral
Jan 9, 17 Mizuho
Underperform
Nov 3, 16 Mizuho
Buy

Institutional Ownership

Similar stocks

BCTX logo
BriaCell Therapeutics (BCTX)
UBX logo
Unity Biotechnology (UBX)
IRIX logo
IRIDEX (IRIX)
BIVI logo
BioVie (BIVI)
MetaVia (MTVA)
LPCN logo
Lipocine (LPCN)
EDSA logo
Edesa Biotech (EDSA)
IINN logo
Inspira Technologies Oxy BHN (IINN)
VSee Health (VSEE)
  • What is the ticker symbol for Eagle Pharmaceuticals?
  • Does Eagle Pharmaceuticals pay dividends?
  • What sector is Eagle Pharmaceuticals in?
  • What industry is Eagle Pharmaceuticals in?
  • What country is Eagle Pharmaceuticals based in?
  • When did Eagle Pharmaceuticals go public?
  • Is Eagle Pharmaceuticals in the S&P 500?
  • Is Eagle Pharmaceuticals in the NASDAQ 100?
  • Is Eagle Pharmaceuticals in the Dow Jones?
  • When was Eagle Pharmaceuticals's last earnings report?
  • When does Eagle Pharmaceuticals report earnings?
  • Should I buy Eagle Pharmaceuticals stock now?

What is the ticker symbol for Eagle Pharmaceuticals?

The ticker symbol for Eagle Pharmaceuticals is NASDAQ:EGRX

Does Eagle Pharmaceuticals pay dividends?

No, Eagle Pharmaceuticals does not pay dividends

What sector is Eagle Pharmaceuticals in?

Eagle Pharmaceuticals is in the Healthcare sector

What industry is Eagle Pharmaceuticals in?

Eagle Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry

What country is Eagle Pharmaceuticals based in?

Eagle Pharmaceuticals is headquartered in United States

When did Eagle Pharmaceuticals go public?

Eagle Pharmaceuticals's initial public offering (IPO) was on February 12, 2014

Is Eagle Pharmaceuticals in the S&P 500?

No, Eagle Pharmaceuticals is not included in the S&P 500 index

Is Eagle Pharmaceuticals in the NASDAQ 100?

No, Eagle Pharmaceuticals is not included in the NASDAQ 100 index

Is Eagle Pharmaceuticals in the Dow Jones?

No, Eagle Pharmaceuticals is not included in the Dow Jones index

When was Eagle Pharmaceuticals's last earnings report?

Eagle Pharmaceuticals's most recent earnings report was on Nov 9, 2023

When does Eagle Pharmaceuticals report earnings?

The next expected earnings date for Eagle Pharmaceuticals is May 15, 2025

Should I buy Eagle Pharmaceuticals stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page